Human Papillomavirus (Vaccine Design)

VLPs from One Variant May Help To Prevent Infection

Published in Cancer Weekly, December 25th, 1995

The finding that two human papillomavirus type 16 (HPV-16) variants are serologically cross-reactive is encouraging news for the development of a genital HPV vaccine.

Grace Cheng, U.S. National Cancer Institute, Bethesda, Maryland and colleagues from the U.S. Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, and the Danish Cancer Society, Copenhagen, Denmark, set out to find whether DNA sequence variants of HPV-16 are distinct serotypes.

Cheng et al. compared the reactivities of women's sera from Zaire (n=97) and Denmark (n=123) ("Divergent Human Papillomavirus Type 16 Variants Are Serologically Cross-Reactive," Journal of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-12-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry